REVIEW PAPER
Handling of endoscopic equipment after use in the case of a patient with suspected prion disease
Jolanta Gruszecka 1, 2  
,  
 
 
More details
Hide details
1
Institute of Nursing and Health Sciences, Medical Faculty, University of Rzeszów, Poland
2
Clinical Department of Microbiology, Regional Clinical Hospital No. 2, Rzeszów, Poland
3
Medical Faculty, University of Rzeszów, Poland
4
Gastroenterology Clinic with Centre for Comprehensive Treatment of Non-specific Inflammatory Bowel Diseases, Clinical Provincial Hospital No. 2, Rzeszów, Poland
CORRESPONDING AUTHOR
Jolanta Gruszecka   

Institute of Nursing and Health Sciences, Medical Faculty, University of Rzeszów, Al.mjr.W.Kopisto 2a, 35-395, Rzeszów, Poland
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Prion diseases are slow-acting, neurodegenerative diseases found in humans and many species of animals. Although they occur very rarely in humans, currently, an increase in this type of disease is being observed, probably as a result of exposure to infectious prions causing BSE disease in cows.

Objective:
The aim of the procedures described in the article is to minimize the risk of human-to-human transfer of all forms of transmissible spongiform encephalopathy, including variant CJD (vCJD) by contaminated medical equipment.

Brief description of the state of knowledge:
All diseases caused by prions, referred to as transmissible spongiform encephalopathies, are fatal. They are characterized by a long development period (up to several decades). Enormous problems are connected with the risk of transferring prions from patient to patient on the surface of instruments used in medical procedures. Laboratory tests indicate that standard disinfection and sterilization procedures may be insufficient to completely remove infectious proteins from contaminated instruments. One of the methods of infection prevention involves taking equipment used for surgery within the brain, tonsils or appendix, into quarantine until biopsy results of these organs have been received that exclude, as far as possible, asymptomatic carriage of prions.

Conclusions:
Whenever possible and justified, disposable-use instruments should be used for invasive surgery in patients with definite, clinically probable cases of CJD (vCJD). After use, these instruments should be incinerated.

 
REFERENCES (54)
1.
Hwang S, Greenlee JJ, Vance NM, Nicholson EM. Source genotype influence on cross species transmission of transmissible spongiform encephalopathies evaluated by RT-QuIC. PLoS One. 2018; December 20. https://doi.org/10.1371/journa....
 
2.
Hwang S, Nicholson EM. Thermodynamic characterization for the denatured state of bovine prion protein and the BSE Associated variant E211K. Prion. 2018; 12: 5–6, 301–309.
 
3.
Igel-Egalon A, Bohl J, Moudjou M, Herzog L, Reine F, Rezaei H, et al. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process? Viruses 2019; 11(5), 429. https://doi.org/10.3390/v11050....
 
4.
Urayama A, Concha-Marambio L, Khan U, Bravo-Alegria J, Kharat V, Soto C. Prions efficiently cross the intestinal barrier after oral administration: Study of the bioavailability, and cellular and tissue distribution in vivo. Scientific Reports. 2016; 6:32338. https://doi.org/10.1038/srep/3....
 
5.
Seed CR, Hewitt PE, Dodd RY, Houston F, Cervenakova L. Creutzfeldt-Jakob disease and blood transfusion safety. Vox Sang. 2018 Apr; 113(3): 220–231. https://doi.org/10.1111/vox./1....
 
6.
Andréoletti O, Litaise C, Simmons H, Corbière F, Lugan S, Costes P, et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog. 2012; 8:e1002782. [PubMed: 22737075].
 
7.
Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR, Onwuzulike K, Puoti G, Cohen ML, Schonberger LB, Cali I. Human prion diseases: surgical lessons learned from iatrogenic prion transmission. Neurosurg Focus. 2016 Jul; 41(1): E10. https://doi.org/10.3171/2016.5....
 
8.
Hilton D. A. Pathogenesis and prevalence of variant Creutzfeldt– Jakob disease. J Pathol. 2006; 208: 134–141. https://doi.org/10.1002/path./....
 
9.
Ward HJ, Everington D, Croes EA, Alperovitch A, DelasnerieLaupretre N, Zerr I, et al. Sporadic Creutzfeldt–Jakob disease and surgery: a case–control study using community controls. Neurology. 2002; 59: 543–548.
 
10.
Flechsig E, Hegyi I, Enari M, Schwarz P, Collinge J, Weissmann C. Transmission of scrapie by steel-surface-bound prions. Mol Med. 2001; 7: 679–684.
 
11.
Taylor DM, Fraser H, McConnell I, Brown DA, Brown KL, Lamza KA, et al. Decontamination studies with the agents of bovine spongiform encephalopathy and scrapie. Arch Virol. 1994; 139: 313–326.
 
12.
Head MW, Ironside JW. vCJD and the gut: implications for endoscopy. Gut. 2007 Jan; 56(1): 9–11. https//:doi.org/10.1136/gut./2006.1019....
 
13.
Axon AT, Beilenhoff U, Bramble MG, Ghosh S, Kruse A, McDonnell GE, et al. Guidelines Committee. European Society of Gastrointestinal Endoscopy (ESGE). Variant Creutzfeldt-Jakob disease (vCJD) and gastrointestinal endoscopy. Endoscopy. 2001; 33(12): 1070–80.
 
14.
Kovaleva J, Peters FTM, van der Mei HC, Degenera JE. Transmission of Infection by Flexible Gastrointestinal Endoscopy and Bronchoscopy. Clin Microbiol Rev. 2013; 26 (2): 231–254.
 
15.
Kazula A, Kazula E. Prion diseases – characteristics, diagnostics and therapy. Farm Pol. 2009; 65(8): 594–604.
 
16.
Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD.Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature. 1996; 383(6602): 685–690.
 
17.
Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, et al. Transmissions to mice indicate that “new variant” CJD is caused by the BSE agent. Nature. 1997; 389(6650): 498–501.
 
18.
Foliaki ST, Lewis V, Islam AMT, Ellett LJ, Senesi M, Finkelstein DI, et al. Early existence and biochemical evolution characterise acutely synaptotoxic PrP SC . PLoS Pathogens. 2019; 15(4). https://doi.org/10.1371/journa....
 
19.
Camp PJ, Damavandi PT, Pickersgill RW, Dove MT. Structure analysis of human Prion protein involved in Sporadic Fatal Insomnia. bioRxiv. 2018; 4. http://dx.doi.org/10.1101/3146....
 
20.
Prusiner SB. Prions. Proc Natl Acad Sci. USA. 1998; 95(23): 13363–13383.
 
21.
McDonnell G, Russell D. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev. 1999; 12(1): 147–179.
 
22.
Hałat Z. Creutzfeldt-Jakob Disease (vCJD) in a capsule. Alergia. 2002; 4(15): 37–42.
 
23.
Aguzzi A, Heppner FL. Pathogenesis of prion diseases: a progress report. Cell Death and Differentiation. 2000; 40(7): 889–902.
 
24.
Nihat A, Mead S. Detection of Creutzfeldt-Jakob disease prions in skin: implications for healthcare. Genome Med. 2018; 10: 22. https://doi.org/10.1186/s13073....
 
25.
Glatzel M, Sigurdson CJ. Recent advances on the molecular pathogenesis of prion diseases. Brain Pathology. 2018; 29(2). https://doi.org/10.1111/bpa.12....
 
26.
Sigurdson CJ, Bartz JC, Glatzel M. Cellular and Molecular Mechanisms of Prion Disease. Annual Rev Pathol: Mechanisms Dis. 2019; 14: 497–516. https://doi.org/10.1146/annure....
 
27.
Thapa S, Abdulrahman B, Abdelaziz DH, Lu L, Aissa MB, Schatzl HM. Overexpression of quality control proteins reduces prion conversion in prion-infected cells. J Biol Chem. 2018; 293(41): 16069–16082. https://doi.org/10.1074/jbc.RA....
 
28.
Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996; 347(9006): 921–925.
 
29.
Bundesgesundheitsblatt – Gesundheitsforschung – Gesundheitsschutz. Variant of Creutzfeldt-Jakob Disease (vCJD). Epidemiology, Detection,Diag nostics and Prevention, with special emphasis on risk minimization of iatrogenic transmission by medical devices, in particular surgical instruments – Final Report of the vCJD Task Force on this topic. 2002; 45(4): 376–394.
 
30.
Gielbert A, Thorne JK, Plater JM, Thorne L, Griffiths PC, Simmons MM, et al. Molecular characterisation of atypical BSE prions by mass spectrometry and changes following transmission to sheep and transgenic mouse models. PLoS One. 2018; November 8. https://doi.org/10.1371/journa....
 
31.
Recommendation of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute (RKI) and the Federal Institute for Drugs and Medical Devices (BfArM). Hygiene requirements for the reprocessing of medical devices. Bundesgesundheitsbl. 2012; 55: 1244–1310.
 
32.
WHO. Guidelines on Tissue Infectivity Distribution in Transmissible Spongiform Encephalopathies. Geneva, Switzerland. 2006; 1–53.
 
33.
Hamaguchi T, Noguchi-Shinohara M, Nakamura Y, Sato T, Kitamoto T, Mizusawa H, Yamada M. Ophthalmic surgery in prion diseases. Emerg Infect Dis. 2007; 13(1): 162–164.
 
34.
Bons N, Mestre-Frances N, Belli P, Cathala F, Gajdusek D, Brown P. Natural and experimental oral infection of nonhuman primates by bovine spongiform encephalopathy agents. Proc Natl Acad Sci. USA. 1999; 96(7): 4046–4051.
 
35.
Beekes M. The variant Creutzfeldt-Jakob Disease (vCJD) – Epidemiology and protective measures against human-to-human transmission. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010; 53(6): 597–605.
 
36.
Rutala WA, Weber DJ. Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol. 2010; 31(2): 107–117.
 
37.
Simon D, Pauli G. Patient care and instrument sterilization in CJD patients and CJD suspected cases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 1998; 41(7): 279–285.
 
38.
WHO. Geneva: World Health Organization; 1999. Infection Control Guidelines for Transmissible Spongiform Encephalopathies. http://www.who.int/csr/resourc... (access: 2018.12.20).
 
39.
Taylor DM. Inactivation of transmissible degenerative encephalopathy agents: A review. Vet J. 2000; 159(1): 10–17.
 
40.
Qin K, O’Donnell M, Zhao R. Doppel: more rival than double to prion. Neuroscience. 2006; 141(1): 1–8.
 
41.
Manuelidis L. Decontamination of Creutzfeldt-Jakob disease and other transmissible agents. J Neurovirol. 1997; 3(1): 62–65.
 
42.
Bertram J, Mielke M, Beekes M, Lemmer K, Baier M, Pauli G. Inactivation and removal of prions in the preparation of medical devices – A contribution to the review and declaration of appropriate procedures. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004; 47(1): 36–40.
 
43.
Rutala WA, Weber DJ. Creutzfeldt-Jakob disease. Recommendations for disinfection and sterilization. Clin Infect Dis. 2001; 32(9): 1348–1356.
 
44.
Beilenhoff U, Biering H, Blum R, Brljak J, Cimbro M, Dumonceau JM, et al. Reprocessing of flexible endoscopes and endoscopic accessories used in gastrointestinal endoscopy: Position Statement of the European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology Nurses and Associates (ESGENA) – Update 2018. Endoscopy 2018; 50(12): 1205–1234.
 
45.
SGNA (Society for Gastroenterology Nurses and Associates) Standards of Infection Prevention in Reprocessing Flexible Gastrointestinal Endoscopes. 2016.
 
46.
Kovaleva J. Infectious complications in gastrointestinal endoscopy and their prevention. Best Pract Res Clin Gastroenterol. 2016; 30(5): 689–704.
 
47.
Michel W, Frister H. Prophylaxis of vCJD transfer and machine methods of tool preparation. Aseptyka. 2002; 4(3): 17–18.
 
48.
Pritzkow S, Wagenfuhr K, Daus ML, Boerner S, Lemmer K, Thomzig A, et al. Quantitative detection and biological propagation of scrapie seeding activity in vitro facilitate use of prions as model pathogens for disinfection. PLoS One. 2011; 6: e20384.
 
49.
Hookey L, Armstrong D, Enns R, Matlow A, Singh H, Love J. Summary of guidelines for infection prevention and control for flexible gastrointestinal endoscopy. Can J Gastroenterol. 2013; 27(6): 347–350.
 
50.
Fichet G, Antloga K, Comoy E, Deslys JP, McDonnell G. Prion inactivation using a new gaseous hydrogen peroxide sterilisation process. J Hosp Infect. 2007; 67(3): 278–286.
 
51.
Fichet G, Comoy E, Duval C, Antloga K, Dehen C, Charbonnier A, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet. 2004; 364(9433): 521–526.
 
52.
Rogez-Kreuz C, Yousfi R, Soufflet C, Quadrio I, Yan ZX, Huyot V, et al. Inactivation of animal and human prions by hydrogen peroxide gas plasma sterilization. Infect Control Hosp Epidemiol. 2009; 30(8): 769–777.
 
53.
Sivakumaran M. Transmission of BSE by blood transfusion. Lancet 2000; 356(9243): 1771–1772.
 
54.
UE. Disposable endoscopes to reduce infection. 2008; Grant agreement ID:18294. https://cordis.europa.eu/resul... (access: 2019.02.26).
 
eISSN:1898-2263
ISSN:1232-1966